IMPL Impel Pharmaceuticals Inc

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K/A

(Amendment No. 1)

 

(Mark One)

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

OR

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-40353

 

IMPEL PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware		26-3058238
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
201 Elliott Avenue West, Suite 260, Seattle, WA (Address of principal executive offices)		98119 (Zip Code)

 

 

Registrant’s telephone number, including area code: (206) 568-1466

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	IMPL	The Nasdaq Stock Market

 

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer		☐			Accelerated filer		☐
Non-accelerated filer		☒			Smaller reporting company		☒
					Emerging growth company		☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

---

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant on June 30, 2022 (the last business day of the Registrant’s second fiscal quarter), based upon the closing price of $9.32 of the Registrant’s common stock as reported on The Nasdaq Global Market, was approximately $119.7 million.

 

The number of shares of Registrant’s Common Stock outstanding as of March 15, 2023 was 23,746,257.

 

Auditor Info: Name – Ernst & Young LLP

Location – Seattle, Washington

PCAOB Number - 42

 

 

 

 

Part III incorporates information by reference from the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the registrant’s 2023 Annual Meeting of Stockholders (the “2023 Proxy Statement”).

 

 

 

 

---

 

EXPLANATORY NOTE

We are filing this Amendment No. 1 to Annual Report on Form 10-K/A (this “Amendment”) to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2023 (the “10-K”). This Amendment is being filed solely to refile the Amended and Restated Bylaws of the Company as an exhibit to this Amendment as required pursuant to Rule 601 under the Securities and Exchange Act of 1934, which due to an inadvertent error occurring during the edgarization process, previously included a non-functioning link.

 

 

 

---

 

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(1) All financial statements;

See Index to Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.

(2) Financial Statement Schedules

All financial statement schedules have been omitted because the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the financial statements or the accompanying notes.

(3) Exhibits

The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.

 

 

 

---

 

EXHIBIT INDEX

				Incorporated by Reference
Exhibit No		Description of Exhibit		Form		File No.		Exhibit		Filing Date		Filed Herewith
3.1		Restated Certificate of Incorporation.		10-Q		001-40353		3.1		June 7, 2021
3.2		Amended and Restated Bylaws.										X
4.1		Form of Registrant's Common Stock Certificate.		S-1/A		333-254999		4.1		April 19, 2021
4.2		Amended and Restated Investors’ Rights Agreement, dated December 4, 2018, by and among the registrant and certain of its stockholders.		S-1		333-254999		4.2		April 2, 2021
4.3		Form of 2021 Convertible Promissory Note.		S-1		333-254999		4.3		April 2, 2021
4.4		Warrant to Purchase Common Stock issued by the Company on July 2, 2021, in favor of Silicon Valley Bank, pursuant to the Security and Loan Agreement, dated as of July 2, 2021, by and between the Registrant and Oxford Finance LLC and Silicon Valley Bank.		10-Q		001-40353		4.3		August 16, 2021
4.5		Warrant to Purchase Common Stock issued by the Company on July 2, 2021, in favor of Oxford Finance, LLC pursuant to the Security and Loan Agreement, dated as of July 2, 2021, by and between the Registrant and Oxford Finance LLC and Silicon Valley Bank.		10-Q		001-40353		4.4		August 16, 2021
4.6		Warrant to Purchase Common Stock issued by the Company on September 30, 2021, in favor of Oxford Finance, LLC pursuant to the Security and Loan Agreement, dated as of July 2, 2021, by and between the Registrant and Oxford Finance LLC and Silicon Valley Bank.		10-Q		001-40353		4.3		November 15, 2021
4.7		Warrant to Purchase Common Stock issued by the Company on September 30, 2021, in favor of Silicon Valley Bank, pursuant to the Security and Loan Agreement, dated as of July 2, 2021, by and between the Registrant and Oxford Finance LLC and Silicon Valley Bank.		10-Q		001-40353		4.4		November 15, 2021
10.1		Form of Indemnity Agreement.		S-1/A		333-254999		10.1		April 19, 2021
10.2+		2008 Equity Incentive Plan, and forms of award agreements.		S-1		333-254999		10.2		April 2, 2021
10.3+		2018 Equity Incentive Plan, and forms of award agreements.		S-1		333-254999		10.3		April 2, 2021
10.4+		2021 Equity Incentive Plan, and forms of award agreements.		S-1/A		333-254999		10.4		April 19, 2021
10.5+		2021 Employee Stock Purchase Plan, and forms of award agreements.		S-1/A		333-254999		10.5		April 19, 2021
10.6+		Employment Agreement, dated April 15, 2021, by and between the registrant and Adrian Adams.		S-1/A		333-254999		10.6		April 19, 2021
10.7+		Employment Agreement, dated April 15, 2021, by and between the registrant and Stephen Shrewsbury.		S-1/A		333-254999		10.7		April 19, 2021
10.8+		Employment Agreement, dated April 15, 2021, by and between the registrant and John Leaman.		S-1/A		333-254999		10.8		April 19, 2021
10.9+		Employment Agreement, dated April 15, 2021, by and between the registrant and Leonard Paolillo.		10-K		001-40353		10.9		March 29, 2022
10.10		BMR-201 Elliott Avenue LLC Lease, dated July 19, 2017, by and between the registrant and BMR-201 Elliott Avenue LLC.		S-1		333-254999		10.9		April 2, 2021
10.11		Security and Loan Agreement, dated as of July 2, 2021, by and between the Registrant and Oxford Finance LLC and Silicon Valley Bank.		10-Q		001-40353		10.4		August 16, 2021
10.12		Credit Agreement and Guaranty dated as of March 17, 2022, by and among Impel Neuropharma, Inc., the subsidiary guarantors		10-Q		001-40353		10.1		May 16, 2022

 

---

 

Incorporated by Reference

Exhibit No

Description of Exhibit

Form

File No.

Exhibit

Filing Date

Filed Herewith

from time to time party thereto, the lenders from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent.

10.13

Revenue Interest Financing Agreement dated as of March 17, 2022, between Impel Neuropharma, Inc., the purchasers from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent.

10-Q

001-40353

10.2

May 16, 2022

10.14

Sales Agreement, dated May 16, 2022, by and between the Registrant and Cowen and Company LLC

S-3

333-264987

1.2

May 16, 2022

10.15

Oaktree Letter Agreement dated as of March 22, 2023, between the Registrant and Oaktree Fund Administration, LLC, as administrative agent.

10-K

001-40353

10.15

March 27, 2023

21.1

Subsidiaries of the Registrant.

10-K

001-40353

21.1

March 27, 2023

23.1

Consent of Ernst & Young LLP, independent registered public accounting firm.

10-K

001-40353

23.1

March 27, 2023

24.1

Powers of Attorney. Reference is made to the signature page hereto.

10-K

001-40353

24.1

March 27, 2023

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.

X

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.

X

32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

10-K

001-40353

32.1

March 27, 2023

32.2

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

10-K

001-40353

32.2

March 27, 2023

101.INS

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).

10-K

001-40353

101.INS

March 27, 2023

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

10-K

001-40353

101.SCH

March 27, 2023

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

10-K

001-40353

101.CAL

March 27, 2023

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

10-K

001-40353

101.DEF

March 27, 2023

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

10-K

001-40353

101.LAB

March 27, 2023

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

10-K

001-40353

101.PRE

March 27, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

10-K

001-40353

104

March 27, 2023

 

+ Indicates management contract or compensatory plan.

* The certification furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany the Form 10-K and are deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act.

 

---

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Impel Pharmaceuticals Inc.
Date: March 31, 2023	By:		/s/ Adrian Adams
			Adrian Adams
			President and Chief Executive Officer
			(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

 

/s/ Adrian Adams		Chief Executive Officer and Director		March 31, 2023
Adrian Adams		(Principal Executive Officer)
/s/ Rajiv Amin		Interim Chief Financial Officer		March 31, 2023
Rajiv Amin		(Principal Accounting and Financial Officer)

 

*		Director		March 31, 2023
David Allison

 

*		Director		March 31, 2023
Tim Nelson

 

*		Director		March 31, 2023
Ali Satvat

 

*		Director		March 31, 2023
Diane Wilfong

 

*		Director		March 31, 2023
Stewart Parker

 

*		Director		March 31, 2023
Mahendra Shah

 

* By: /s/ Adrian Adams

Adrian Adams Attorney-in-fact

 

 

---